Human ADRB2 Stable Cell Line - HEK293

The Beta-2 Adrenergic Receptor (ADRB2) is a quintessential, comprehensively characterized Class A G protein-coupled receptor (GPCR) that serves as a primary mediator of physiological responses to endogenous catecholamines, specifically epinephrine and norepinephrine. Biologically, the activation of ADRB2 classically couples to the Gs heterotrimeric G protein complex. This interaction directly stimulates adenylyl cyclase activity, driving a rapid intracellular accumulation of cyclic AMP (cAMP) and the subsequent activation of Protein Kinase A (PKA) signaling cascades. This specific signaling axis plays a fundamental role in mediating smooth muscle relaxation throughout the body, most notably inducing profound bronchodilation in the respiratory tract and vasodilation in skeletal muscle vascular beds. Because of these critical physiological functions, the ADRB2 receptor is a major, heavily validated therapeutic target for severe respiratory conditions, particularly asthma and chronic obstructive pulmonary disease (COPD).

The Human ADRB2 Stable Cell Line - HEK293 is built upon the well-characterized Human Embryonic Kidney 293 lineage, renowned for its robust adherent growth, high transfectability, and stable epithelial morphology. In standard laboratory environments, this stable in vitro model provides a highly reproducible platform for the high-throughput screening (HTS) of novel pharmacological agents, particularly focusing on short- and long-acting beta-agonists (SABAs and LABAs), selective antagonists, and allosteric modulators. Because ADRB2 efficiently signals through the Gs/cAMP pathway, these engineered cells are perfectly optimized for sensitive, homogeneous cAMP accumulation assays, allowing researchers to rapidly and accurately quantify receptor activation or inhibition in real-time. Furthermore, the cell line is extensively utilized for precise pharmacological profiling, including evaluating primary ligand binding affinities, mapping receptor desensitization and internalization kinetics (frequently via beta-arrestin recruitment assays), and characterizing biased agonism profiles.